Increasing Rate of Bacterial Infections Due to Climate Change Driving Adoption of Bacteriophages: Fact.MR Report

An increase in the incidence of bacterial infections owing to climate change, an aging population, and rising global travel is set to increase global demand for bacteriophages. The global bacteriophage market is calculated to reach US$ 50.3 million in 2024 and climb to a valuation of US$ 86.6 million by the end of 2034, as mentioned in this updated market report by Fact.MR, a market research and competitive intelligence provider.

Several public and private companies are investing in phage therapies, which is anticipated to generate opportunities for global market players. They are expected to carry out effective phage-based treatments through extensive R&D activities. Increasing interest in the development of drugs, such as immunological disorders and infectious diseases is also driving global market growth opportunities.

Advancements in bacteriophage-based products and the incorporation of advanced technologies in the production process are set to widen opportunities for market players in the coming 10 years. Supportive government policies and the presence of well-established healthcare infrastructure, including hospitals, clinics, etc. in some regions are presenting lucrative opportunities for market players.

For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=5558

Key Takeaway from the Market Study:

• Worldwide demand for bacteriophages is anticipated to increase at 5.6% CAGR from 2024 to 2034.
• Sales of bacteriophages in South Korea are evaluated to rise at 6.2% CAGR from 2024 to 2034.
• North America is approximated to hold 36.3% share of the global market by the end of 2034.
• Phage probiotics are anticipated to contribute 69.1% of the global market revenue share by 2034-end.
• Worldwide sales of bacteriophages through hospital pharmacies are evaluated to increase at a CAGR of 5.4% and reach US$ 48.7 million by 2034-end.

“Increasing demand for bacteriophages is attributed to their growing use as a dietary supplement, assistance in minimizing food borne infections, and rising expenditure in phage therapy,” says a Fact.MR analyst.

Rising Use of Bacteriophages in Gastroenterology as Dietary Supplement

Demand for bacteriophages in gastroenterology is projected to increase at a CAGR of 6.3% and reach a valuation of US$ 42.4 million by the end of 2034. In recent years, there has been an increase in the requirements for bacteriophages to prevent and treat gastrointestinal symptoms and disorders. Moreover, the rising use of bacteriophages as one of the popular dietary supplements for improving gut health is anticipated to contribute to market growth.

Bacteriophage Industry News

Key manufacturers in the bacteriophage market are focusing on geographical expansion while continuously innovating products to align with consumer needs. To achieve growth, they are implementing various strategic approaches, including new product development, collaborations, strengthening supply chain systems, acquisitions, and agreements. Additionally, they are prioritizing the delivery of high-quality products to enhance their market presence and competitiveness.

For instance, in August 2021, Carillon Miami Wellness Resort partnered with The Biostation to introduce novel functional medicine practices at its 70,000-square-foot wellness and spa facility. Similarly, in November 2021, IntraLytix Inc. and AB Agri entered into a partnership to explore the application of bacteriophages in animal feed as a promising alternative to antibiotics and similar drugs. These strategic initiatives reflect the industry's commitment to innovation and expanding the potential applications of bacteriophages.

Key Market Players

Armata Pharmaceuticals Inc., Life Extension, Microgen, Arthur Andrew Medical, Probiotic America, IntraLytix Inc., Designs for Health, ADM, The Biostation, Biochimpharm, and Micreos Human Health are some of the prominent companies manufacturing bacteriophages.

Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=S&rep_id=5558

More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the bacteriophage market, presenting historical demand data (2018 to 2023) and forecast statistics for the period (2024 to 2034).

The study divulges essential insights into the market based on product type (phage probiotics, phage therapeutics), route of administration (oral, topical), application (gastroenterology, respiratory infections treatment, skin infection treatment, wound prophylaxis, urological infection treatment), and distribution channel (retail pharmacies, hospital pharmacies, online pharmacies), across six major regions of the world (North America, Europe, East Asia, Latin America, South Asia & Oceania, and MEA).

Check out More Related Studies Published by Fact.MR Research:

Antibacterial drugs market, the market is projected to expand at a CAGR of 2.6% over the forecast period (2021 to 2031), and reach a valuation of over US$ 62 billion by 2031-end, and surpassing US$ 51 billion by 2025.

Sales of bactericides are expected to increase at a CAGR of 4.6% from 2022 to 2032. Currently, the global bactericides market is valued at US$ 16.98 billion and is anticipated to reach US$ 25.02 billion by 2032.

Microbiology culture market is poised for significant growth over the assessment period (2025 to 2035), the market is expected to reach USD 16,694 million by 2035, up from USD 7,549 million in 2024. The market is projected expand at a value Compound Annual Growth Rate (CAGR) of 7.5% during the forecast period of (2025 to 2035).

Dietary supplement market is projected at US$ 190.12 billion in 2024 and has been evaluated to expand at 8% CAGR to reach a value of US$ 410.46 billion by 2034-end.

Liquid dietary supplement market size is calculated at US$ 49.4 billion for 2024 and is forecasted to jump to a valuation of US$ 120 billion by 2034-end, expanding at a stellar 9.2% CAGR over the next ten years (2024 to 2034).